(in millions) | Cardiac and Vascular Group | Restorative Therapies Group | Total | ||||||||
Balance as of April 29, 2011 | $ | 2,662 | $ | 6,858 | $ | 9,520 | |||||
Goodwill as a result of acquisitions | — | 404 | 404 | ||||||||
Purchase accounting adjustments, net | 6 | 38 | 44 | ||||||||
Currency adjustment, net | (32 | ) | (2 | ) | (34 | ) | |||||
Balance as of April 27, 2012 | $ | 2,636 | $ | 7,298 | $ | 9,934 | |||||
Goodwill as a result of acquisitions | — | 414 | 414 | ||||||||
Purchase accounting adjustments, net | — | 3 | 3 | ||||||||
Currency adjustment, net | (12 | ) | (10 | ) | (22 | ) | |||||
Balance as of April 26, 2013 | $ | 2,624 | $ | 7,705 | $ | 10,329 |
(in millions) | Purchased Technology and Patents | Trademarks and Tradenames | Acquired IPR&D | Other | Total | ||||||||||||||
Amortizable intangible assets as of April 26, 2013 | |||||||||||||||||||
Original cost | $ | 3,896 | $ | 408 | $ | 363 | $ | 104 | $ | 4,771 | |||||||||
Accumulated amortization | (1,702 | ) | (320 | ) | — | (76 | ) | (2,098 | ) | ||||||||||
Carrying value | $ | 2,194 | $ | 88 | $ | 363 | $ | 28 | $ | 2,673 | |||||||||
Weighted average original life (in years) | 12.5 | 11.8 | N/A | 8.8 | |||||||||||||||
Amortizable intangible assets as of April 27, 2012 | |||||||||||||||||||
Original cost | $ | 3,604 | $ | 373 | $ | 370 | $ | 148 | $ | 4,495 | |||||||||
Accumulated amortization | (1,440 | ) | (307 | ) | — | (101 | ) | (1,848 | ) | ||||||||||
Carrying value | $ | 2,164 | $ | 66 | $ | 370 | $ | 47 | $ | 2,647 | |||||||||
Weighted average original life (in years) | 12.6 | 10.3 | N/A | 9.6 |
(in millions) Fiscal Year | Amortization Expense | ||
2014 | $ | 337 | |
2015 | 321 | ||
2016 | 308 | ||
2017 | 286 | ||
2018 | 271 | ||
Thereafter | 787 | ||
$ | 2,310 |